Announced Fri, 26 Jun · 18:52 IST
Wanbury Board approves new subsidiary, appoints EY as Internal Auditor
Strategic Transactions View source PDF
WANBURY · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
+1.8%1-day move
₹275.00
prior close
₹274.35
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-0.2+1.0+1.1+2.2+1.8+4.8+3.9+3.7+3.5-1.3+24.0———
Up moveDown movePending
AI summary
Wanbury Limited board approved incorporating a new subsidiary called Wanbury Skin Health Limited in India. The company will hold 82 percent equity, investing about Rs 4.10 lakh via 41,000 shares of Rs 10 each, in cash. The board also appointed Ernst and Young LLP as Internal Auditor and ABK and Associates as Cost Auditor for FY 2026-27.
Likely market impact
Minor capital outlay for a new pharma subsidiary. Auditor appointments are routine. Limited immediate impact on shareholders.